VYNE THERAPEUTICS INC (VYNE) Stock Price & Overview
NASDAQ:VYNE • US92941V3087
Current stock price
The current stock price of VYNE is 0.6145 USD. Today VYNE is down by -2.46%. In the past month the price increased by 3.03%. In the past year, price decreased by -63.85%.
VYNE Key Statistics
- Market Cap
- 20.475M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.61
- Dividend Yield
- N/A
VYNE Stock Performance
VYNE Stock Chart
VYNE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to VYNE. When comparing the yearly performance of all stocks, VYNE is a bad performer in the overall market: 88.92% of all stocks are doing better.
VYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VYNE. While VYNE has a great health rating, there are worries on its profitability.
VYNE Earnings
On February 27, 2026 VYNE reported an EPS of -0.11 and a revenue of 130.00K. The company beat EPS expectations (38.5% surprise) and missed revenue expectations (-36.27% surprise).
VYNE Forecast & Estimates
10 analysts have analysed VYNE and the average price target is 3.32 USD. This implies a price increase of 439.46% is expected in the next year compared to the current price of 0.6145.
For the next year, analysts expect an EPS growth of -52.27% and a revenue growth 16.67% for VYNE
VYNE Groups
Sector & Classification
VYNE Financial Highlights
Over the last trailing twelve months VYNE reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 34.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.81% | ||
| ROE | -95.38% | ||
| Debt/Equity | 0 |
VYNE Ownership
VYNE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.05 | 858.976B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 567.035B | ||
| MRK | MERCK & CO. INC. | 22.35 | 286.006B | ||
| PFE | PFIZER INC | 8.97 | 152.277B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9 | 116.079B | ||
| ZTS | ZOETIS INC | 16.28 | 48.642B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.311B | ||
| VTRS | VIATRIS INC | 5.3 | 15.302B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.23 | 12.151B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.022B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.67B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.269B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.6 | 3.995B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VYNE
Company Profile
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Info
IPO: 2018-01-25
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807 US
CEO: David Domzalski
Employees: 10
Phone: 18668207754
VYNE THERAPEUTICS INC / VYNE FAQ
What does VYNE do?
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Can you provide the latest stock price for VYNE THERAPEUTICS INC?
The current stock price of VYNE is 0.6145 USD. The price decreased by -2.46% in the last trading session.
What is the dividend status of VYNE THERAPEUTICS INC?
VYNE does not pay a dividend.
What is the ChartMill rating of VYNE THERAPEUTICS INC stock?
VYNE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ownership structure of VYNE THERAPEUTICS INC (VYNE)?
You can find the ownership structure of VYNE THERAPEUTICS INC (VYNE) on the Ownership tab.
What is the Short Interest ratio of VYNE THERAPEUTICS INC (VYNE) stock?
The outstanding short interest for VYNE THERAPEUTICS INC (VYNE) is 0.67% of its float.